“So normally, we should have also in Q3, most of it in Q4.”

In context

“get my sense of when we get this 3Q update, will that be based on the sales we’re seeing in the quarter or more your interpretation of the trend we’re seeing for vaccinations, so just setting expectations? And the second part was on the EU contract renegotiation. Just any additional color you can provide on how different, I guess, the terms end up being for 2023 relative to what was reflected in the 2023 guidance? Dr. Albert Bourla: I can take it very quickly. Look, if you see, we will have basically July, August, September in the third quarter. So the vaccinations with the new will start in September, hopefully. Of course, what we expect is that we will have approval by the end of the August. And we are ready with product already now. So we have -- so the production will not be an issue. So normally, we should have also in Q3, most of it in Q4. But what really will clarify us at the end of Q3 plus also the month that takes after Q3 until we give -- we present our Q3 results. It is really vaccination rate. That is what will inform. And the net price, right? Because everything after all, we’ll know way better what the net price. Also very big part of this uncertainty for Comirnaty will go away. On the EU contract renegotiation, I don’t know if you noticed, I did say that when we gave our guidance, we were expecting that we will have incorporated assumptions that we will renegotiate the EU contract. And our assumptions were assuming that we will do over three years. Now we did over four years that creates a pressure to our guidance, but then we had some contracts that we didn’t expect, guidance in Latin America, particularly but of”